Island Pharmaceuticals Ltd (AU:ILA) has released an update.
Island Pharmaceuticals Ltd has announced the strategic appointment of Chris Ntoumenopoulos as a Non-Executive Director, coinciding with the retirement of Dr. David Brookes from the Board. Ntoumenopoulos is recognized for his two decades of financial market savvy, particularly in healthcare, and his current directorship roles in several ASX-listed companies. The company is also progressing with its Phase 2a/b clinical trials for ISLA-101, a promising drug for dengue fever prevention and treatment.
For further insights into AU:ILA stock, check out TipRanks’ Stock Analysis page.
